(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012307 A1

(51) International Patent Classification[7]: C07D 487/04, A61K 31/519, A61P 25/24, 3/10 // (C07D 487/04, 249:00, 235:00)

(21) International Application Number: PCT/EP2004/051455

(22) International Filing Date: 12 July 2004 (12.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP03/50310 16 July 2003 (16.07.2003) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FREYNE, Eddy Jean Edgard** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LOVE, Christopher John** [GB/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **COOYMANS, Ludwig Paul** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VANDERMAESEN, Nele** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **BUIJNSTERS, Peter Jacobus Johannes Antonius** [NL/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **WILLEMS, Marc** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **EMBRECHTS, Werner Constant Johan** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,*

[Continued on next page]

(54) Title: TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS



(I)



(a-1)

(57) Abstract: This invention concerns a compound of formula (I), a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary arnine and a stereochernic ally isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R^1 represents hydrogen; aryl; formyI; C_{1-6}alkylcarbonyl, C_{1-6}alkyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkyl substituted with formyl, C_{1-6}alkylearbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyloxy; or C_{1-6}alkyloxyC_{1-6}alkylcarbonyl optionally substituted with C_{1-6}alkyloxycarbonyl; X represents a direct bond; -$(CH_2)_{n3}$or -$(CH_2)_{m4}$-X_{1a}-X_{1b}-; R^2 represents C_{3-7}cycloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom. selected from 0, S or N; benzoxazolyl or a radical of formula (a-1), wherein said R^2 substituent may optionally be substituted; R^3 represents halo; hydroxy; optionally substituted C_{1-6}alkyl; C_{2-6}a]kenyl or C_{2-6}alkynyl, each optionally substituted; optionally substituted polyhaloC_{1-6}alkyl; optionally substituted C_{1-6}alkyloxy; optionally substituted polyhaloC_{1-6}alkyloxy; C_{1-6}alkylthio; polyhaloC_{1-6}a]kylthio; C_{1-6}a]kyloxycarbonyl; C_{1-6}alkylcarbonyloxy; C_{1-6}alkylearbonyl; polyhaloC_{1-6}alkylcarbonyl; cyano; carboxyl; aryloxy; arylthio; arylcarbonyl; NR^{6b} R^{7b}; C(=O)-NR ^{6b} R^{7b}; -NR^5-C(=O)R^5;'-S(=O)$_{nl}$-R^{8a}; -$NR^5S(=O)_{nl}$ -R ^{8a};-NR ^{5} -S(=O)$_{nl}$-R ^{8a} ; -S-CN; -NR^5 -CN;R^4 represents hydrogen; halo; hydroxy; optionally substituted C_{1-4}alkyl; C_{2-4}alkenyl or C_{2-4}alkynyl, each optionally substituted; polyha]oC_{1-3}alkyl; optionally substituted C_{1-4}alkyloxy; polyhalo-C_{1-3}alkyloxy; C_{1-4}alkylthio; polyhaloC_{1-3}alkylthio C_{1-4}alkyloxycarbonyl; C_{1-4}alkylcarbonyloxy; C_{1-4}alkylcarbonyl; polyhatoC_{1-4}alkylcarbonyl; nitro; cyano; carboxyl; NR^{10} R^{11}; C(=O)NR^{10}-R^{11};NR^5-C(=O)-$NR^{10}R^{11}$;-NR^5 -C(=O)-R^5; -S(=O)$_{nl}$,-R^{12} -NR^5-S(=O)$_{nl}$-R^{12} ; -S-CN; -NR^5 -CN; their use, pharmaceutical compositions comprising them and processes for their preparation.

WO 2005/012307 A1

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.